Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5652W HIGH $2.55
Volume
53.20 K
Value Traded
18.01 K
Short % Float
15.73%
-8.77%Week
+8.71%1 Month
+106.6%3 Month
+21.88%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
45.16 M
EPS (TTM)
-2.46
P/E Ratio
-
Ent. Value
44.79 M
Total Shares
28.96 M
Float Shares
5.22 M
Insiders
83.91%
Institutions
6.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CELU Catalyst Timeline
Dated clinical, regulatory and corporate events for Celularity Inc. Class A Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Celularity Inc. Class A Common Stock
148Total events
6Upcoming
36Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Equity OfferingCorporate
Initial closing of private placement generating over $10 million in gross cash proceeds
▲Partnership / LicenseCorporate
Celularity and MuseCell Innovations announce U.S. manufacturing collaboration
▼Quarterly UpdateCorporate
Received Nasdaq notification for non-compliance due to delayed 10-Q filings
▲Other Regulator Milestonecenplacel-LEx-US Regulatory
Availability of cenplacel-L for investigational use under Florida law
▲Partnership / Licensecenplacel-LCorporate
Collaboration with Fountain Life for clinical channel
▲FDA Filing AcceptedRegulatory Filing
Filed Annual Report on Form 10-K for fiscal year ended December 31, 2025
▲Partnership / LicenseCorporate
Closing of transaction with NexGel for biomaterials portfolio
▲Partnership / LicenseCorporate
Celularity enters strategic license deal for placental-derived biomaterials portfolio
▼Restructuring LayoffsCorporate
Celularity reduces workforce as part of organizational realignment
●Other Regulator MilestoneEx-US Regulatory
CMS flat payment rate of $127.28 per sq cm for skin substitutes takes effect
Skin substitute productssource ↗
▲Other Regulator MilestoneEx-US Regulatory
CMS withdraws skin substitute Local Coverage Determinations that were to take effect Jan 1, 2026
Skin substitute products for diabetic foot ulcers and venous leg ulcerssource ↗
▲Equity OfferingCorporate
Closing of financing transactions with Philip A. Barach, including senior secured term loan and secured convertible note
◆Timing GuidancePresentation
Intends to submit 510(k) notification for FUSE Bone Void Filler
bone void filler in pelvis, extremities, posterior-lateral spinal fusionsource ↗
◆Management ChangeCorporate
CFO David Beers terminated without cause; Joseph DosSantos appointed interim CFO
●IND SubmissionIND
IND submission expected for TCX-102 program
Acute Myelogenous Leukemia (AML)source ↗
▲Partnership / LicenseCorporate
Master Services Collaboration Agreement with BlueSphere Bio for manufacturing of cell therapy products
◆First Patient DosedBSB-1001Trial
First patient dosing anticipated in TCX-101 program
Acute Myelogenous Leukemia (AML)source ↗
◆Timing GuidancePresentation
Intends to submit 510(k) notification for Celularity Tendon Wrap
management and protection of tendon injuriessource ↗
▲Quarterly UpdateCorporate
Filed Q2 2024 Form 10-Q on November 6, 2024, becoming current with quarterly filings
▲Quarterly UpdateReboundCorporate
Rebound product contributed ~$9M in expected net sales through October 2024
▲Partnership / LicenseReboundCorporate
Acquisition of Rebound product from Sequence LifeScience
wound care and soft tissue repairsource ↗
▲AcquisitionReboundCorporate
Acquisition of Rebound product from Sequence LifeScience
full thickness placental-derived allograft matrixsource ↗
▲FDA Filing AcceptedRegulatory Filing
Filed annual report on Form 10-K for fiscal year 2023 within compliance period
◆Oral PresentationPresentation
Additional data submitted for consideration as presentation at ASCO
HER2 positive cancerssource ↗
◆Oral PresentationPresentation
Initial data for preclinical oncology T cell program targeting HER2 positive cancers presented at AACR
HER2 positive cancerssource ↗
▲Quarterly UpdateCorporate
Expected net sales of biomaterial products and biobanking businesses for Q4 2023 and full year 2023
▲Partnership / LicenseCorporate
Multi-year Research Collaboration Services Agreement with Regeneron
▼Equity OfferingCorporate
$3 million registered direct offering of Class A common stock and warrants
◆Topline ReadoutCYNK-001Clinical Data
Preliminary results from Phase 1 trial of CYNK-001 in R/R AML and MRD positive AML
relapsed refractory acute myeloid leukemia (R/R AML)source ↗
▼Trial DiscontinuedCYNK-001Trial
Phase 1 trial of CYNK-001 closed to further enrollment
acute myeloid leukemia (AML)source ↗
●Preclinical PoCCYNK-301Preclinical
CYNK-301 is a pre-clinical next-generation CAR-NK cell therapy candidate
relapsed refractory acute myeloid leukemia (R/R AML)source ↗
▲Partnership / LicenseCorporate
Exclusive territory agreement with CH Trading Group for Halal-Certified products in >100 countries
◆Pipeline PrioritizationCorporate
Pipeline prioritization and targeted expense reductions to align operating priorities
Past FDA Catalysts and PDUFA Decisions
How CELU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-12-01 | CYNK-001 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CELU program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CYNK-001 | relapsed refractory acute myeloid leukemia (R/R AML) | Phase 1 | 2023-04-27 | 50% of patients in one cohort achieved significant clinical responses; two of four patients achieved an objective response at Day 28; one of three patients achieved MRD negativityRead More | Celularity Contact: Paul Graves, Chief Communications Officer Celularity Inc. paul.graves@celularity.com CELULARITY ANNOUNCES CLINICAL DATA ON HUMAN PLACENTAL-DERIVED UNMODIFIED ALLOGENEIC NATURAL KILLER CERead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brigido StephenOfficer (Pres., Functional Regeneration) | Disposition | -268 9,474 held | $1.28 | 04/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CELU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0.3 % (200 %) | 624.00 K | 183.60 K | 129.5% ( 103.60 K) |
CELU Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CELU ranks across every disease it competes in
Competitive Position is a premium feature
See how CELU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCELU News
-CELU
Sep 30, 2026Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
Celularity Inc. announced the anticipated opening of Fontaine Vitale, a regenerative medicine center in Bali, Indonesia, set for Q1 2027. This facility will be the first in the ASEAN region to offer placenta-derived stem cell therapy, leveraging Celularity's technology. The center aims to provide a range of wellness and regenerative services, presenting a new market opportunity for the company.
Read more →-CELU
Sep 29, 2026Celularity Announces Naveen Jain to Join Board of Directors
Celularity Inc. has announced the appointment of Naveen Jain to its Board of Directors. Jain, founder of Viome Life Sciences, will contribute his expertise in personalized health and technology to enhance Celularity's regenerative medicine initiatives. His appointment reflects the company's commitment to proactive health solutions and expanding its commercial reach.
Read more →-CELU
Sep 24, 2026▲ +14.8%on this newsshared move
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
Celularity Inc. has announced an initial financing closing of over $10 million as part of a recapitalization plan aiming for up to $28 million. The plan includes significant operating improvements, such as a reduction in cash burn and a focus on revenue-generating opportunities. The company expects to achieve positive monthly operating cash flow by the end of Q1 2027, supported by its existing product inventory and enhanced manufacturing capabilities.
Read more →-CELU
Aug 27, 2026▲ +138.5%on this news
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
Celularity Inc. has formed a manufacturing partnership with MuseCell Innovations to produce Dezawa MuseCells at its facility in Florham Park, New Jersey. This collaboration aims to enhance the production capabilities of the Dezawa MuseCell platform in the U.S. market. The partnership is expected to contribute to advancements in cell therapy.
Read more →-CELU
Aug 25, 2026▲ +9.9%on this news· ran to +162% by day 1shared move
Celularity Provides Update Regarding Nasdaq Listing Compliance
Celularity Inc. has received a notification from Nasdaq regarding non-compliance due to delayed filings of its Quarterly Reports for the periods ending March 31 and June 30, 2026. The company must submit a plan to regain compliance by September 4, 2026. Despite this, trading of its stock continues without immediate effect on its listing status.
Read more →-CELU
Jun 4, 2026Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
Celularity Inc. and Fountain Life Management have announced the availability of cenplacel-L, a placental-derived cell therapy, for investigational use in Florida. This follows new legislation that allows licensed physicians to utilize certain unapproved therapies. The initiative aims to create a scalable pathway for regenerative medicine, leveraging Celularity's manufacturing capabilities and clinical-grade products.
Read more →-CELU
Jun 3, 2026Celularity Releases CEO Letter to Shareholders
Celularity Inc. has released a letter from CEO Robert J. Hariri detailing the company's strategic focus on placental-derived cellular therapies, particularly cenplacel-L. The company has streamlined operations and out-licensed its biomaterials business to strengthen its financial position. Despite challenges in the capital markets, there is strong physician interest in cenplacel-L, positioning Celularity for potential growth in the regenerative medicine sector.
Read more →-CELU
Jun 3, 2026Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Celularity Inc. has appointed Rick Gonzalez as Chief Commercial Officer to enhance its global commercial strategy. His experience in biotechnology and medical technology is expected to drive growth for the company's cenplacel-L and Lifebank offerings. The appointment comes as Celularity aims to expand access to its regenerative therapies amid increasing physician interest.
Read more →-CELU
May 29, 2026Celularity Receives Nasdaq Notice Regarding Form 10-Q
Celularity Inc. received a notice from Nasdaq regarding its delayed filing of the Form 10-Q for Q1 2026, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until July 28, 2026, to submit a compliance plan, with a potential extension until November 16, 2026. Despite the notice, trading of CELU stock remains unaffected.
Read more →-CELU
May 4, 2026Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Celularity Inc. has filed its Form 10-K for the fiscal year ending December 31, 2025, regaining compliance with Nasdaq's listing requirements. The company has undertaken strategic initiatives, including the out-licensing of its biomaterials portfolio and a reduction in liabilities by about $13 million. Leadership emphasizes a focused approach towards advancing regenerative medicine and creating long-term value.
Read more →-CELU
Apr 21, 2026Celularity Announces Closing of Transaction with NexGel
Celularity Inc. has completed a transaction with NexGel, where NexGel acquired assets related to Celularity's biomaterials portfolio. The deal, valued at $13.3 million, allows Celularity to focus on its therapeutic pipeline while potentially earning additional milestone payments. This transaction also helps Celularity retire significant debt, enhancing its financial position.
Read more →-CELU
Apr 20, 2026Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Inc. received a notice from Nasdaq for not filing its Form 10-K for the fiscal year ending December 31, 2025. The company has 60 days to submit a compliance plan and may receive an extension of up to 180 days to regain compliance. Despite the notice, trading of its stock continues without immediate effect.
Read more →-CELU
Mar 12, 2026Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
Celularity Inc. has reaffirmed its strategic partnership with NEXGEL to enhance its biomaterials franchise. This collaboration focuses on established products and new 510(k) pathway opportunities. Celularity will manufacture the licensed products at its FDA-compliant facility, aiming to capitalize on market growth and regulatory clarity. The transaction is expected to close by April 15, 2026.
Read more →-CELU
Mar 10, 2026▲ +11.2%on this news
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
Celularity Inc. has announced a strategic commercialization partnership for its placental-derived biomaterials, expected to generate up to $35 million in payments. The deal allows Celularity to focus on its longevity therapeutics while retaining exclusive manufacturing rights. An organizational realignment will reduce operating expenses and streamline operations, enhancing capital efficiency.
Read more →-CELU
Feb 10, 2026Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
Celularity Inc. announced it has received $12.2 million from the sale of its unused New Jersey net operating losses and research tax credits. This transaction, facilitated by the New Jersey Economic Development Authority, provides the company with non-dilutive capital to enhance liquidity and support its regenerative medicine initiatives. The funds will aid in advancing their cell therapies targeting aging mechanisms.
Read more →-CELU
Dec 29, 2025▼ -10.4%on this news
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
Celularity's CEO, Dr. Robert J. Hariri, expressed support for the CMS's withdrawal of skin substitute Local Coverage Determinations (LCDs), which would have affected other companies' products. Despite the withdrawal, Celularity's Biovance® and Biovance 3L remain eligible for Medicare coverage. The new Medicare payment policy for skin substitutes will still apply, ensuring reimbursement at a flat rate.
Read more →About Celularity Inc. Class A Common Stock
Headquarters170 PARK AVE, FLORHAM PARK, NJ, 07932
BIOPHARMAWATCH ELITE PLUS
Trade the next CELU catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime